In India, vitiligo is managed by dermatologists. Vitiligo is a chronic autoimmune skin disease in which CD8+ T cells destroy epidermal melanocytes, producing the sharply defined milk-white patches that define the disorder. It affects roughly 0.5-2% of people worldwide, with prevalence around 0.5-1% in the United States and Europe and as high as 8.8% in some regions of India and Gujarat.
Vitiligo (ICD-10: L80) is an acquired autoimmune disease characterized by the selective destruction of epidermal melanocytes, the pigment-producing cells that synthesize melanin. CD8+ cytotoxic T cells, driven largely by the interferon-gamma and CXCL9/CXCL10 chemokine axis, recognize melanocyte antigens such as tyrosinase and target them for destruction, leaving sharply demarcated milk-white macules and patches without functional pigment. The condition is now classified, by the Vitiligo Global Issues Consensus Conference (Ezzedine 2012), into two principal forms: non-segmental vitiligo (NSV, including the generalized and acrofacial subtypes), which is bilateral, symmetric, and chronic with periods of activity; and segmental vitiligo (SV), which follows a unilateral, dermatomal-like distribution and typically stabilizes within 1-2 years. Mixed and unclassified variants exist.
The key symptoms of Vitiligo are: Sharply demarcated, milk-white or chalk-white macules and patches with a clear border separating depigmented from normally pigmented skin — most often on the hands, face, around the mouth and eyes, elbows, knees, and over bony prominences., Symmetric distribution in non-segmental disease, with new patches commonly appearing at sites of friction, pressure, or skin injury — the Koebner phenomenon — typically 10-14 days after trauma in roughly 20-30% of patients., Premature greying or whitening of scalp hair, eyebrows, eyelashes, or beard (leukotrichia) within affected patches, indicating loss of follicular melanocytes and a poorer repigmentation prognosis at that site., Trichrome appearance at the edge of expanding patches, with a pale intermediate zone between fully depigmented centre and normally pigmented surrounding skin — a sign of active disease., Confetti-like depigmentation — small 1-5 mm white macules at the periphery of larger patches — a clinical marker of rapidly progressive vitiligo., Patches are typically asymptomatic, but a minority of patients report mild itching, burning, or tingling at the edge of active lesions in the days before visible enlargement., Slow, unpredictable progression with alternating stable and active phases; some patients have decades-long quiescence after initial flare while others progress steadily..
Vitiligo is a clinical diagnosis confirmed by a trained dermatologist on examination. The hallmark is a sharply demarcated, depigmented (not merely hypopigmented) macule or patch with normal skin texture and no scale. Wood's lamp examination — long-wave ultraviolet light in a dark room — is the single most useful bedside tool: depigmented vitiligo skin emits a bright bluish-white fluorescence due to loss of epidermal melanin, while hypopigmented mimics such as pityriasis alba, post-inflammatory hypopigmentation, and nevus depigmentosus appear less striking. Wood's lamp also reveals subclinical patches and helps map disease extent for treatment planning. The 2012 Vitiligo Global Issues Consensus distinguishes non-segmental from segmental disease — a distinction that drives prognosis and therapy. Disease activity is graded clinically (Vitiligo Disease Activity score, VIDA) and by signs of activity such as trichrome borders, confetti-like depigmentation, hypochromic edges, and Koebner phenomenon. Total body surface area is quantified using the Vitiligo Extent Score (VES) or the Vitiligo Area Scoring Index (VASI). Skin biopsy is reserved for atypical presentations — typically to distinguish vitiligo from mycosis fungoides hypopigmented variant, lichen sclerosus, or leprosy. Histology shows absence of melanocytes and melanin in lesional skin with preserved skin architecture, sometimes with a sparse perilesional lymphocytic infiltrate in active disease. Because vitiligo clusters with other autoimmune diseases, every newly diagnosed adult patient should be screened for thyroid autoimmunity (TSH and anti-thyroid peroxidase antibodies); additional screening for vitamin B12 and fasting glucose is appropriate based on symptoms or family history. Children with vitiligo should be screened annually for thyroid disease through adolescence.
Vitiligo is a lifelong condition without a definitive cure, but treatment outcomes have improved markedly with the introduction of topical JAK inhibitors and refined phototherapy protocols. Roughly 60-75% of motivated patients with non-segmental disease achieve at least 25% repigmentation with narrowband UVB combined with a topical agent, and 30-50% achieve 50% or greater repigmentation over 6-12 months. Facial and truncal patches respond best; hands, feet, lips, and bony prominences respond least. Segmental disease tends to stabilize within 1-2 years of onset and responds best to surgical techniques, with 75-90% repigmentation rates in selected patients. Relapse after stopping therapy occurs in 40-50% within 12 months unless maintenance topical tacrolimus or proactive twice-weekly therapy is used. Vitiligo does not affect life expectancy directly, but the psychological burden — depression rates of 25-35% in published cohorts, especially in darker skin types and adolescents — measurably affects quality of life and is now considered a core treatment target. Early intervention during active disease, before extensive follicular melanocyte loss occurs, predicts the best long-term outcomes.
See a dermatologist for any new depigmented patch that does not return after a few weeks, especially if it appears on the face, hands, or genitals, if patches are spreading rapidly, if eyelashes or eyebrows are turning white inside patches, or if first-line topical therapy fails after 3 months. Specialist referral is essential before starting phototherapy, oral mini-pulse steroids, or surgical interventions, and for children and adolescents where treatment choice and psychosocial support must be tailored together.
Find specialists →First signs of repigmentation typically appear after 8-12 weeks of consistent therapy as small dotted islands of pigment around hair follicles within a depigmented patch. Visible patch shrinkage develops over 3-6 months with topical therapy and 4-8 months with phototherapy combined with topical agents. Maximum response is usually reached at 12-18 months, after which further gains are slow. Surgical repigmentation after non-cultured epidermal cell suspension or punch grafting becomes visible at 6-12 weeks post-procedure and matures over 6-12 months. Maintenance therapy with twice-weekly topical tacrolimus reduces 12-month relapse rates from roughly 40% to under 10% (Cavalié 2015 J Invest Dermatol).
Aim for 150 minutes of moderate aerobic activity per week plus two resistance sessions, the standard adult target. Exercise reduces stress and improves overall immune regulation. Apply sunscreen on exposed patches before outdoor activity, wear UPF clothing on prolonged sun exposure, and shower promptly afterward to reduce friction-related Koebner spread from tight workout clothes. Public-pool chlorine is generally tolerated, but rinse thoroughly afterward.
Choose a board-certified dermatologist with experience in vitiligo and access to narrowband UVB phototherapy in their clinic or a partnering centre. For surgical treatment, look for centres offering non-cultured epidermal cell suspension or suction blister grafting and willing to share photographic outcomes. Dedicated vitiligo clinics in academic medical centres or national reference networks (Global Vitiligo Foundation centres in the US, BAD-affiliated centres in the UK) offer the highest integration of medical, surgical, phototherapy, and psychological care.
Medically reviewed by AIHealz Medical Editorial Board · May 12, 2026
Ranked by patient outcomes and specialized experience.
Specialists who treat Vitiligo. Get expert guidance and personalized care.